Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

Jaya Kittur, Ryan A. Knudson, Terra L. Lasho, Christy M. Finke, Naseema Gangat, Alexandra P. Wolanskyj, Chin Yang Li, Wenting Wu, Rhett P. Ketterling, Animesh D Pardanani, Ayalew Tefferi

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

BACKGROUND. JAK2V617F occurs in approximately 50% of patients with essential thrombocythemia (ET). Qualitative studies of mutation analysis have previously reported an association between JAK2V617F and advanced age, higher hemoglobin level, higher leukocyte count, and lower platelet count. A possible association with thrombotic complication has also been considered. METHODS. Allele-specific, quantitative polymerase chain reaction (PCR) analysis for JAK2V617F was performed in 176 patients with ET using genomic DNA from archived bone marrow, which was collected within 1 year (n = 72 patients), between 1 and 5 years (n = 64 patients), or after 5 years (n = 40 patients) of diagnosis. RESULTS. JAK2V617F was detected in 96 patients (55%), in whom mutant allele burden ranged from 1% to 100% (median, 6.3%). Neither mutational frequency (P = .37) nor mutant allele burden (P = .62) was affected by the timing of bone marrow sample collection. The presence of JAK2V617F was found to be significantly associated with higher hemoglobin level (P < .0001), lower platelet count (P = .001), higher leukocyte count (P = .008), increased incidence of venous thrombosis occurring after diagnosis (P = .02), and older age at diagnosis (P = .03). All but age retained significance in multivariable analysis. In mutation-positive patients (n = 96 patients), JAK2V617F allele burden clustered between 1% and 22% in 94 cases, in whom it correlated directly and significantly with platelet and leukocyte counts, palpable splenomegaly at diagnosis, and venous thrombosis occurring after diagnosis. The latter 2 associations remained significant with the inclusion of the remaining 2 outlier cases with 100% mutant allele burden; in addition, an association with male gender became evident. CONCLUSIONS. JAK2V617F allele burden imparts additional phenotypic effects in ET.

Original languageEnglish (US)
Pages (from-to)2279-2284
Number of pages6
JournalCancer
Volume109
Issue number11
DOIs
StatePublished - Jun 1 2007

Fingerprint

Essential Thrombocythemia
Alleles
Platelet Count
Leukocyte Count
Venous Thrombosis
Bone Marrow
Mutation
Splenomegaly
Hemoglobins
Polymerase Chain Reaction
DNA
Incidence

Keywords

  • Allele burden
  • Essential thrombocythemia
  • JAK2V617F

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kittur, J., Knudson, R. A., Lasho, T. L., Finke, C. M., Gangat, N., Wolanskyj, A. P., ... Tefferi, A. (2007). Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer, 109(11), 2279-2284. https://doi.org/10.1002/cncr.22663

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. / Kittur, Jaya; Knudson, Ryan A.; Lasho, Terra L.; Finke, Christy M.; Gangat, Naseema; Wolanskyj, Alexandra P.; Li, Chin Yang; Wu, Wenting; Ketterling, Rhett P.; Pardanani, Animesh D; Tefferi, Ayalew.

In: Cancer, Vol. 109, No. 11, 01.06.2007, p. 2279-2284.

Research output: Contribution to journalArticle

Kittur, J, Knudson, RA, Lasho, TL, Finke, CM, Gangat, N, Wolanskyj, AP, Li, CY, Wu, W, Ketterling, RP, Pardanani, AD & Tefferi, A 2007, 'Clinical correlates of JAK2V617F allele burden in essential thrombocythemia', Cancer, vol. 109, no. 11, pp. 2279-2284. https://doi.org/10.1002/cncr.22663
Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007 Jun 1;109(11):2279-2284. https://doi.org/10.1002/cncr.22663
Kittur, Jaya ; Knudson, Ryan A. ; Lasho, Terra L. ; Finke, Christy M. ; Gangat, Naseema ; Wolanskyj, Alexandra P. ; Li, Chin Yang ; Wu, Wenting ; Ketterling, Rhett P. ; Pardanani, Animesh D ; Tefferi, Ayalew. / Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. In: Cancer. 2007 ; Vol. 109, No. 11. pp. 2279-2284.
@article{1702f50c56ad48bd97d147b2febc903c,
title = "Clinical correlates of JAK2V617F allele burden in essential thrombocythemia",
abstract = "BACKGROUND. JAK2V617F occurs in approximately 50{\%} of patients with essential thrombocythemia (ET). Qualitative studies of mutation analysis have previously reported an association between JAK2V617F and advanced age, higher hemoglobin level, higher leukocyte count, and lower platelet count. A possible association with thrombotic complication has also been considered. METHODS. Allele-specific, quantitative polymerase chain reaction (PCR) analysis for JAK2V617F was performed in 176 patients with ET using genomic DNA from archived bone marrow, which was collected within 1 year (n = 72 patients), between 1 and 5 years (n = 64 patients), or after 5 years (n = 40 patients) of diagnosis. RESULTS. JAK2V617F was detected in 96 patients (55{\%}), in whom mutant allele burden ranged from 1{\%} to 100{\%} (median, 6.3{\%}). Neither mutational frequency (P = .37) nor mutant allele burden (P = .62) was affected by the timing of bone marrow sample collection. The presence of JAK2V617F was found to be significantly associated with higher hemoglobin level (P < .0001), lower platelet count (P = .001), higher leukocyte count (P = .008), increased incidence of venous thrombosis occurring after diagnosis (P = .02), and older age at diagnosis (P = .03). All but age retained significance in multivariable analysis. In mutation-positive patients (n = 96 patients), JAK2V617F allele burden clustered between 1{\%} and 22{\%} in 94 cases, in whom it correlated directly and significantly with platelet and leukocyte counts, palpable splenomegaly at diagnosis, and venous thrombosis occurring after diagnosis. The latter 2 associations remained significant with the inclusion of the remaining 2 outlier cases with 100{\%} mutant allele burden; in addition, an association with male gender became evident. CONCLUSIONS. JAK2V617F allele burden imparts additional phenotypic effects in ET.",
keywords = "Allele burden, Essential thrombocythemia, JAK2V617F",
author = "Jaya Kittur and Knudson, {Ryan A.} and Lasho, {Terra L.} and Finke, {Christy M.} and Naseema Gangat and Wolanskyj, {Alexandra P.} and Li, {Chin Yang} and Wenting Wu and Ketterling, {Rhett P.} and Pardanani, {Animesh D} and Ayalew Tefferi",
year = "2007",
month = "6",
day = "1",
doi = "10.1002/cncr.22663",
language = "English (US)",
volume = "109",
pages = "2279--2284",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

AU - Kittur, Jaya

AU - Knudson, Ryan A.

AU - Lasho, Terra L.

AU - Finke, Christy M.

AU - Gangat, Naseema

AU - Wolanskyj, Alexandra P.

AU - Li, Chin Yang

AU - Wu, Wenting

AU - Ketterling, Rhett P.

AU - Pardanani, Animesh D

AU - Tefferi, Ayalew

PY - 2007/6/1

Y1 - 2007/6/1

N2 - BACKGROUND. JAK2V617F occurs in approximately 50% of patients with essential thrombocythemia (ET). Qualitative studies of mutation analysis have previously reported an association between JAK2V617F and advanced age, higher hemoglobin level, higher leukocyte count, and lower platelet count. A possible association with thrombotic complication has also been considered. METHODS. Allele-specific, quantitative polymerase chain reaction (PCR) analysis for JAK2V617F was performed in 176 patients with ET using genomic DNA from archived bone marrow, which was collected within 1 year (n = 72 patients), between 1 and 5 years (n = 64 patients), or after 5 years (n = 40 patients) of diagnosis. RESULTS. JAK2V617F was detected in 96 patients (55%), in whom mutant allele burden ranged from 1% to 100% (median, 6.3%). Neither mutational frequency (P = .37) nor mutant allele burden (P = .62) was affected by the timing of bone marrow sample collection. The presence of JAK2V617F was found to be significantly associated with higher hemoglobin level (P < .0001), lower platelet count (P = .001), higher leukocyte count (P = .008), increased incidence of venous thrombosis occurring after diagnosis (P = .02), and older age at diagnosis (P = .03). All but age retained significance in multivariable analysis. In mutation-positive patients (n = 96 patients), JAK2V617F allele burden clustered between 1% and 22% in 94 cases, in whom it correlated directly and significantly with platelet and leukocyte counts, palpable splenomegaly at diagnosis, and venous thrombosis occurring after diagnosis. The latter 2 associations remained significant with the inclusion of the remaining 2 outlier cases with 100% mutant allele burden; in addition, an association with male gender became evident. CONCLUSIONS. JAK2V617F allele burden imparts additional phenotypic effects in ET.

AB - BACKGROUND. JAK2V617F occurs in approximately 50% of patients with essential thrombocythemia (ET). Qualitative studies of mutation analysis have previously reported an association between JAK2V617F and advanced age, higher hemoglobin level, higher leukocyte count, and lower platelet count. A possible association with thrombotic complication has also been considered. METHODS. Allele-specific, quantitative polymerase chain reaction (PCR) analysis for JAK2V617F was performed in 176 patients with ET using genomic DNA from archived bone marrow, which was collected within 1 year (n = 72 patients), between 1 and 5 years (n = 64 patients), or after 5 years (n = 40 patients) of diagnosis. RESULTS. JAK2V617F was detected in 96 patients (55%), in whom mutant allele burden ranged from 1% to 100% (median, 6.3%). Neither mutational frequency (P = .37) nor mutant allele burden (P = .62) was affected by the timing of bone marrow sample collection. The presence of JAK2V617F was found to be significantly associated with higher hemoglobin level (P < .0001), lower platelet count (P = .001), higher leukocyte count (P = .008), increased incidence of venous thrombosis occurring after diagnosis (P = .02), and older age at diagnosis (P = .03). All but age retained significance in multivariable analysis. In mutation-positive patients (n = 96 patients), JAK2V617F allele burden clustered between 1% and 22% in 94 cases, in whom it correlated directly and significantly with platelet and leukocyte counts, palpable splenomegaly at diagnosis, and venous thrombosis occurring after diagnosis. The latter 2 associations remained significant with the inclusion of the remaining 2 outlier cases with 100% mutant allele burden; in addition, an association with male gender became evident. CONCLUSIONS. JAK2V617F allele burden imparts additional phenotypic effects in ET.

KW - Allele burden

KW - Essential thrombocythemia

KW - JAK2V617F

UR - http://www.scopus.com/inward/record.url?scp=34249071097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249071097&partnerID=8YFLogxK

U2 - 10.1002/cncr.22663

DO - 10.1002/cncr.22663

M3 - Article

VL - 109

SP - 2279

EP - 2284

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -